Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BuSpar Antitrust Settlement Is Two-Times Sales During Extended Patent Life

Executive Summary

Bristol-Myers Squibb's proposed $535 mil. payment to settle BuSpar antitrust litigation amounts to more than twice the sales of the anxiety drug during the four months of extended exclusivity for the product that prompted the suits

You may also be interested in...



Mylan/Aventis Terminate Zagam Deal; Mylan Clears Books Of Pending Suits

Mylan and Aventis are ending the Zagam marketing deal under a settlement of claims arising from supply problems with the antibiotic

Mylan/Aventis Terminate Zagam Deal; Mylan Clears Books Of Pending Suits

Mylan and Aventis are ending the Zagam marketing deal under a settlement of claims arising from supply problems with the antibiotic

Bristol/FTC Settlement Brings PTO Standards Into Spotlight

The Federal Trade Commission's antitrust settlement with Bristol-Myers Squibb may bring Patent & Trademark Office standards for pharmaceutical patents into the spotlight

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel